Jessie S. Luken

Jessie S. Luken

Auto-generated profile, based on publicly available information

Jessie S. Luken

Department of Immunohaematology Diagnostic Services Sanquin Diagnostic Services Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Transfusion
Verified
Journal Article
Open access
PDF file
JLJessie S. Luken
Jessie S. Luken
CFClaudia C. Folman
Claudia C. Folman
MLMichaël V. Lukens
Michaël V. Lukens
JMJohan H. Meekers
Johan H. Meekers
PLPeter C. Ligthart
Peter C. Ligthart
MHMasja de Haas
Masja de Haas
Background: During pregnancy, maternal red blood cell (RBC) antibodies can lead to life‐threatening fetal hemolysis and anemia. Women can become immunized by a pregnancy or an unmatched transfusion. Our aim was to quantify the effect of a nationwide K‐matched transfusion policy for women of childbearing age potential to prevent K‐immunization in pregnancy.Study Design and Methods: In this nation‐wide policy change evaluation study we determined the occurrence of RBC antibodies before and after introduction of a K‐matched transfusion policy and evaluated the cause K alloimmunization 10 years after introduction of this measure. K‐matched transfusion for females under 45 years of age is advised in the Dutch transfusion guideline since 2004. We used laboratory data from pregnancies with RBC antibodies identified in the period 1999‐2018 obtained as part of a population‐based screening program in the Netherlands.Results: Tests of 36 286 pregnancies produced a positive antibody screening result which concerned anti‐K in 1550 pregnancies. The occurrence of anti‐K decreased from 67.9 to 20.2 per 100 000 pregnancies. The relative risk reduction was 0.70 which largely exceeded the relative risk reduction of 0.27 for antibodies against RBC antigens for which no preventive matching is required. The number of pregnancies at risk for anti‐K‐mediated disease decreased from 9.7 to 4.2 per 100 000 pregnancies.Conclusions: A K‐matched transfusion policy is associated with a major decrease in a number of pregnant women with anti‐K and pregnancies at risk for anti‐K‐mediated disease. A relatively simple measure is now shown to impact prevention of hemolytic disease in the fetus and newborn.

29 January 2024 in Vox Sanguinis
Verified
Journal Article
Closed access
MWMerel L. Wemelsfelder
Merel L. Wemelsfelder
RWRonald H. G. van de Weem
Ronald H. G. van de Weem
JLJessie S. Luken
Jessie S. Luken
MHMasja de Haas
Masja de Haas
RNRené W. L. M. Niessen
René W. L. M. Niessen
MJMart Janssen
Mart Janssen

2 November 2021 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
RWRonald H. G. van de Weem
Ronald H. G. van de Weem
MWMerel L. Wemelsfelder
Merel L. Wemelsfelder
JLJessie S. Luken
Jessie S. Luken
MHMasja de Haas
Masja de Haas
RNRené W. L. M. Niessen
René W. L. M. Niessen
MJMart Janssen
Mart Janssen

10 September 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
JLJessie S. Luken
Jessie S. Luken
CFClaudia C. Folman
Claudia C. Folman
JMJohan H. Meekers
Johan H. Meekers
MLMichael V. Lukens
Michael V. Lukens
CSC. Ellen Van Der Schoot
C. Ellen Van Der Schoot
MHMasja de Haas
Masja de Haas

6 June 2022 in Transfusion Medicine
Verified
Journal Article
Closed access
JLJessie S. Luken
Jessie S. Luken
SRSebastien P. Ritsema
Sebastien P. Ritsema
MWMerel M. van der Wal
Merel M. van der Wal
CSC. Ellen Van Der Schoot
C. Ellen Van Der Schoot
EREtiënne A. J. A. Rouwette
Etiënne A. J. A. Rouwette
MJMart Janssen
Mart Janssen

1 January 2016 in Immunohematology
Verified
Journal Article
Closed access
PDF file
JLJessie S. Luken
Jessie S. Luken
FDFikreta Danovic
Fikreta Danovic
MHMasja de Haas
Masja de Haas
MKM.M.W. Koopman
M.M.W. Koopman